This study tests a combination of two drugs, pembrolizumab and lenvatinib, for women with advanced cervical cancer that did not respond to other treatments. These drugs aim to boost the immune system's response against the cancer. Pembrolizumab is a type of drug called an immune checkpoint inhibitor, which helps the immune system detect and fight cancer cells. Lenvatinib is a targeted therapy that blocks proteins like VEGF, which can help cancer grow.
The study will be conducted in two stages, with a total of 35 participants. In the first stage, 11 patients will be tested, and if at least two show a positive response, the study will proceed to the second stage with 24 more patients. Participants must be at least 18 years old, not pregnant or breastfeeding, and must have advanced cervical cancer that has progressed after previous treatments.
Key Points:
- The study involves two stages with a total of 35 participants.
- Participants must be women with advanced cervical cancer.
- Both drugs aim to enhance the immune response against cancer.